Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P1JJ
|
|||
| Former ID |
DNC007214
|
|||
| Drug Name |
6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H24N6O4
|
|||
| Canonical SMILES |
CCC1C(C(C(O1)N2C=NC3=C(N=C(N=C32)OCCC4=CNC5=CC=CC=C54)N)O)O
|
|||
| InChI |
1S/C21H24N6O4/c1-2-14-16(28)17(29)20(31-14)27-10-24-15-18(22)25-21(26-19(15)27)30-8-7-11-9-23-13-6-4-3-5-12(11)13/h3-6,9-10,14,16-17,20,23,28-29H,2,7-8H2,1H3,(H2,22,25,26)/t14-,16-,17-,20-/m1/s1
|
|||
| InChIKey |
USRXNKLXHDLOMQ-WVSUBDOOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Inhibitor | [1] |
| Adenosine A3 receptor (ADORA3) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.